Diagnóstico y manejo del síndrome de ovario poliquístico: una perspectiva dermatológica

  • Ana María Rivas
  • Luz Adriana Vásquez
  • María Isabel Arredondo
Palabras clave: síndrome de ovario poliquístico, acné, hirsutismo, resistencia a la insulina, trastornos menstruales, alopecia androgénica polycystic ovary syndrome, acne, hirsutism, insulin resistance, menstrual irregularity, pattern alopecia


El síndrome de ovario poliquístico afecta 5% a 10% de las mujeres en edad fértil. Es un síndrome heterogéneo caracterizado por anovulación crónica hiperandrogénica, secundaria a una disfunción ovárica intrínseca. Aunque las pacientes afectadas se ven muy perturbadas por las manifestaciones cutáneas, que incluyen acné, hirsutismo, alopecia y acanthosis nigricans, el síndrome de ovario poliquístico puede tener implicaciones mucho más serias que las encontradas en la piel; con frecuencia causa irregularidades menstruales e infertilidad y, además, está agravado por una hiperinsulinemia resistente a la insulina, con el consecuente riesgo de diabetes mellitus y síndrome metabólico.
En este artículo se discuten las manifestaciones cutáneas del síndrome de ovario poliquístico, los diagnósticos diferenciales, la aproximación diagnóstica y las opciones terapéuticas.

Biografía del autor/a

Ana María Rivas

Médica cirujana, RIII en Dermatología, Universidad Pontificia Bolivariana, Medellín, Colombia

Luz Adriana Vásquez

Médica dermatóloga, Hospital Pablo Tobón Uribe, Medellín, Colombia

María Isabel Arredondo

Médica dermatóloga, Hospital Pablo Tobón Uribe, Medellín, Colombia

Referencias bibliográficas

1. Essah PA, Wickham EP 3rd, Nunley JR, Nestler JE. Dermatology of androgen-related disorders. Clin Dermatol. 2006;24:289-98.
2. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453-62.
3. Rosenfield RL. What every physician should know about polycystic ovary syndrome. Dermatol Ther. 2008;21:354-61.
4. Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol. 2007;8:201-19.
5. Stein I, Leventhal M. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181-5.
6. Zawadski J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. En: Dunaif A, Givens J, Haseltine F, editors. Polycystic ovary syndrome. Boston, MA: Blackwell Scientific; 1992 p. 377-84.
7. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.
8. Lowe P, Kovacs G, Howlett D. Incidence of polycystic ovaries and polycystic ovary syndrome amongst women in Melbourne, Australia. Aust NZJ Obstet Gynaecol. 2005:45:17-9.
9. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237-45.
10. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456-88.
11. Nisenblat V, Norman RJ. Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes. 2009;16:224-31.
12. Nam MM, Strauss JF. Genetics of polycystic ovarian syndrome. Clin Obstet Gynecol. 2007;50:188-204.
13. Urbanec M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2007;3:103-11.
14. Unluturk U, Harmanci A, Kocaefe C, Yildiz BO. The genetic basis of the polycystic ovary syndrome: a literature review including discussion of PPARgamma. PPAR Res. 2007; 2007:1-23.
15. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008;10:1-21.
16. Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2248-56.
17. Blank SK, McCartney CR, Helm KD, Marshall JC. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. Semin Reprod Med. 2007;25:352-9.
18. Sagnella F, Apa R, Guido M, Villa P, Spadoni V, Miceli F, Lanzone A. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase. Fertil Steril. 2009;91:1857-63.
19. Yildiz BO, Azziz R. The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord. 2007;8:331-42.
20. Carmina E, Lobo RA. Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes. J Endocrinol Invest. 2007;30:111-6.
21. Moran C, Renteria JL, Moran S, Herrera J, Gonzalez S, Bermudez JA. Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome. Fertil Steril. 2008;90:2310-7.
22. Qu J, Wang Y, Wu X, Gao L, Hou L, Erkkola R. Insulin resistance directly contributes to androgenic potential within ovarian theca cells. Fertil Steril. 2009;91:1990-7.
23. Baillargeon JP, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril. 2007;88:886-93.
24. van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. Fertil Steril. 2000;74:49-58.
25. van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents. Hum Reprod. 1999;14:2223-9.
26. Mastorakos G, Lambrinoudaki I, Creatsas G. Polycystic ovary syndrome in adolescents: current and future treatment options. Paediatr Drugs. 2006;8:311-8.
27. Hart R. PCOS and infertility. Panminerva Med. 2008;50:305-14.
28. Navaratnarajah R, Pillay OC, Hardiman P. Polycystic ovary syndrome and endometrial cancer. Semin Reprod Med. 2008;26:62-71.
29. Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf). 2007;67:735-42.
30. Shumak SL. Even lean women with PCOS are insulin resistant. BMJ. 2009;338:b954.
31. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141-6.
32. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol. 2003;101:995-1007.
33. Al Robaee A, Al-Zolibani A, Al Shobaili HA, Aslam M. Update on hirsutism. Acta Dermatovenerol Alp Panonica Adriat. 2008;17:103-19.
34. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W. Beyond adrenal and ovarian androgen generation: increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Meta. 2003;88:2760-6.
35. Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:737-54.
36. Hatch R, Rosefield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140:815-30.
37. Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol. 2002;16:275-84.
38. Karrer-Voegeli S, Rey F, Reymond MJ, Meuwly JY, Gaillard RC, Gomez F. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of patients investigated for hyperandrogenism. Medicine (Baltimore). 2009;88:32-45.
39. Walton S, Cunliffe WJ, Keczkes K, Early AS, McGarrigle HH, Katz M, Reese RA. Clinical, ultrasound and hormonal markers of androgenicity in acne vulgaris. Br J Dermatol. 1995;133:249-53.
40. Timpatanapong P, Rojanasakul A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol. 1997;24:223-9.
41. Henze C, Hinney B,WuttkeW. Incidence of increased androgen levels patients suffering from acne. Dermatology (Switzerland). 1998;196:53-4.
42. Thiboutot D, Gilliland K, Light J, Lookingbill D. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol. 1999;135:1041-5.
43. Seirafi H, Farnaghi F, Vasheghani-Farahani A, Alirezaie NS, Esfahanian F, Firooz A, Ghodsi SZ. Assessment of androgens in women with adult-onset acne. Int J Dermatol. 2007;46:1188-91.
44. Carmina E, Rosato F, Jannì A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91:2-6.
45. Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol. 1988;19:831-6.
46. Paus R, Olsen EA, Messenger AG. Hair Growth Disorders. En: Wolff K, Goldsmith LA, Katz ST, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick´s Dermatology in General Medicine. Seventh edition. New York: McGraw Hill; 2008. p. 753-77.
47. Olsen EA, Hordinsky M, Roberts JL, Whiting DA. Dermatologic Consortium for Women's Health. Female pattern hair loss. J Am Acad Dermatol. 2002;47:795.
48. Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: a practical approach to evaluation and management. Dermatol Online J. 2008;14:2.
49. Panidis D, Skiadopoulos S, Rousso D, Ioannides D, Panidou E. Association of acanthosis nigricans with insulin resistance in patients with polycystic ovary syndrome. Br J Dermatol. 1995;132:936-41.
50. Rosenfield RL. Clinical practice. Hirsutism [Comment in: N Engl J Med 2006;354:1533-5; author’s reply 1533-5]. N Engl J Med. 2005;353:2578-88.
51. Bulun SE, Adashi EY. The physiology and pathology of the female reproductive system. En: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams’ textbook of endocrinology. Tenth edition. Philadelphia: Saunders; 2002. p. 587-664.
52. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol. 2004;18:685-706.
53. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006;19:210-23.
54. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694-8.
55. Porter MB. Polycystic ovary syndrome: the controversy of diagnosis by ultrasound. Semin Reprod Med. 2008;26:241-51.
56. New MI. An update of congenital adrenal hyperplasia. Ann NY Acad Sci. 2004;1038:14-43.
57. Harper JC. Antiandrogen therapy for skin and hair disease. Dermatol Clin. 2006;24:137-43.
58. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008;61:151-7.
59. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2009;8:CD004425.
60. George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg. 2008;27:188-96.
61. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69:2-15.
62. Batukan C, Muderris II, Ozcelik B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol. 2007;23:38-44.
63. Cancer CGoHFiB. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713-27.
64. Venturoli S, Marescalchi O, Colombo FM, Macrelli S, Ravaioli B, Bagnoli A, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab. 1999;84:1304-10.
65. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152:466-73.
66. Barth JH, Cherry CA, Wojnarowska F, Dawber RP. Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Clin Endocrinol (Oxf). 1991;35:5-10.
67. Franks S, Layton A, Glasier A. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Hum Reprod. 2008;23:231-2.
68. Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2009;CD000194.
69. Shaw JC. Low dose adjunctive spironolactone in the treatment of acne in women: A retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43:498-502.
70. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004;22:419-28.
71. Müderris II, Bayram F, Güven M. Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol. 2000;14:38-41.
72. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. Comparison of flutamida and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril. 1994;61:281-7.
73. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79:91-5.
74. Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol. 1999;141:361-7.
75. Unluhizarci K, Ozel D, Tanriverdi F, Karaca Z, Kelestimur F. A comparison between finasteride, flutamide, and finasteride plus flutamide combination in the treatment of hirsutism. J Endocrinol Invest. 2009;32:37-40.
76. Castelo-Branco C, Del Pino M. Hepatotoxicity during lowdose flutamide treatment for hirsutism. Gynecol Endocrinol. 2009;25:419-422.
77. Price VH, Roberts JL, Hordinsky M, Olsen EA, Savin R, Bergfeld W, et al. Falta citar tres autores Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43:768-76.
78. Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142:298-302.
79. Erenus M, Yucelten D, Durmusoglu F, Gürbüz O. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil Steril. 1997;68:1000-3.
80. Venturoli S, Marescalchi O, Colombo FM, Macrelli S, Ravaioli B, Bagnoli A, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab. 1999;84:1304-10.
81. Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol. 2002;147:217-21.
82. Wasniewska M, Arrigo T, Crisafulli G, Lombardo F, Messina MF, Salzano G, Valenzise M, De Luca F. Recovery of acanthosis nigricans under prolonged metformin treatment in an adolescent with normal weight. J Endocrinol Invest. 2009;32:939-40.
83. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107:E55.
84. Yilmaz M, Biri A, Karakoç A, Törüner F, Bingöl B, Cakir N, Tiras B, Ayvaz G, Arslan M. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest. 2005;28:1003-8.
Cómo citar
Rivas AM, Vásquez LA, Arredondo MI. Diagnóstico y manejo del síndrome de ovario poliquístico: una perspectiva dermatológica. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 15 de febrero de 2019 [citado 27 de noviembre de 2022];18(2):78-90. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/196


Los datos de descargas todavía no están disponibles.
Artículo de revisión